CC BY-NC-ND 4.0 · Thromb Haemost 2019; 119(11): 1767-1772
DOI: 10.1055/s-0039-1696718
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity

1  Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, A. Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
,
Maribel Mirabet
2  Assay Development Department, Biokit, Barcelona, Spain
,
3  Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
,
Marina Biganzoli
1  Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, A. Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
,
Lucia Schiavone
1  Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, A. Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
,
Susanna Faraudo
4  Clinical Affairs Department, Biokit, Barcelona, Spain
,
Daniel Mane-Padros
4  Clinical Affairs Department, Biokit, Barcelona, Spain
,
David Giles
2  Assay Development Department, Biokit, Barcelona, Spain
,
Josep Serra-Domenech
2  Assay Development Department, Biokit, Barcelona, Spain
,
Silvia Blanch
2  Assay Development Department, Biokit, Barcelona, Spain
,
Silvia Maria Trisolini
5  Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy
,
Luca Facchini
6  Hematology Unit, Oncology Department, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, Reggio Emilia, Italy
,
Erminia Rinaldi
7  Hematology Unit, A. Perrino Hospital, Brindisi, Italy
,
1  Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, A. Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
3  Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
› Author Affiliations
Further Information

Publication History

12 March 2019

13 July 2019

Publication Date:
06 October 2019 (online)

  

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy (TMA) characterized by the severe deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (< 10%). Rapid ADAMTS13 testing is crucial for an early diagnosis and optimal management of acute TTP. We evaluated the performance of the HemosIL AcuStar ADAMTS13 activity assay (Instrumentation Laboratory, Bedford, Massachusetts, United States), a fully automated chemiluminescent immunoassay with an analytical time of 33 minutes. A method comparison study was performed on 176 samples from 49 healthy donors and 127 TMA patients (109 TTP, 7 atypical hemolytic uremic syndrome, 11 other TMAs), comparing this new assay with an in-house FRETS-VWF73 assay and a commercial enzyme-linked immunosorbent assay (ELISA) (TECHNOZYM ADAMTS-13 Activity, Technoclone GmbH, Vienna, Austria). Agreement between methods was assessed with focus on ADAMTS13 activity less than 10%, the medical decision level relevant for TTP diagnosis. The HemosIL AcuStar ADAMTS13 Activity showed good correlation with both the FRETS-VWF73 (r = 0.96) and ELISA (r = 0.96) methods. Slope of the Passing–Bablok regression was 1.05 for FRETS-VWF73 and 1.02 for ELISA, and absolute bias at the medical decision level was +0.1 and +0.3%, respectively. The study also revealed high agreement with FRETS-VWF73 (kappa 0.97) and ELISA (kappa 0.98) methods in classifying TTP patients with a severe deficiency of ADAMTS13 activity. Because of its short turnaround time and full automation, the HemosIL AcuStar ADAMTS13 activity assay might become the assay of choice to rapidly test ADAMTS13 activity in plasma and thus establish the diagnosis of acute TTP in emergency settings.

Authors' Contributions

C.V. designed the study, performed experiments, performed quality control, interpreted the results, and wrote the manuscript. M.M. developed the HemosIL AcuStar ADAMTS13 Activity assay, designed the study, performed quality control, interpreted the results, and wrote the manuscript. I.M. designed the study, interpreted the results, and critically reviewed the manuscript. M.B. collected clinical and/or experimental data and performed experiments and critically reviewed the manuscript. L.S. collected clinical and/or experimental data and critically reviewed the manuscript. S.F. designed the study, analyzed and interpreted the results, and critically reviewed the manuscript. D.M.-P. designed the study, analyzed and interpreted the results, and critically reviewed the manuscript. D.G. designed the study, interpreted the results, and critically reviewed the manuscript. J.S.-D. interpreted the results and critically reviewed the manuscript. S.B. developed the HemosIL AcuStar ADAMTS13 Activity assay, collected experimental data, and critically reviewed the manuscript. S.M.T. enrolled patients, and critically reviewed the manuscript. L.F. enrolled patients and critically reviewed the manuscript. E.R. enrolled patients and critically reviewed the manuscript. F.P. designed the study, enrolled patients, interpreted the results, and critically reviewed the manuscript. All authors approved the final version of the manuscript.


Supplementary Material